PRECISION BIOSCIENCES INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
DTIL$9.68-8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8-K | 001-38841 | 3.1 | 4/1/2019 | |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8-K | 001-38841 | 3.1 | 2/13/2024 | |
| 3.3 | Amended and Restated Bylaws of Precision BioSciences, Inc. | 8-K | 001-38841 | 3.2 | 12/22/2023 | |
| 4.1 | Form of March 2024 Warrant | 8-K | 001-38841 | 4.1 | 3/1/2024 | |
| 10.1† | License Agreement, dated January 7, 2024, by and among Precision BioSciences, Inc. and TG Cell Therapy, Inc. and its parent company, TG Therapeutics, Inc. | 10-K | 001-38841 | 10.2 | 3/27/2024 | |
| 10.2 | Executive Employment Agreement, dated January 22, 2024, by and between Michael Amoroso and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.1 | 1/23/2024 | |
| 10.3 | Executive Employment Agreement, dated January 22, 2024, by and between Alex Kelly and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.2 | 1/23/2024 | |
| 10.4 | Precision BioSciences, Inc. 2019 Incentive Award Plan, as Amended and Restated | 8-K | 001-38841 | 10.1 | 6/10/2024 | |
| 10.5 | Eighth Amendment to Loan and Security Agreement, entered into as of June 21, 2024, by and between Banc of California (f/k/a Pacific Western Bank) and Precision BioSciences, Inc. | * | ||||
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 10.6 | Amendment to the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan | S-8 | 333-280618 | 99.4 | 7/1/2024 | |
| 10.7 | Amended and Restated Loan and Security Agreement, entered into as of July 31, 2024, by and between Banc of California and Precision BioSciences, Inc. | * | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 101.INS | Inline XBRL Instance Document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | * | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | * | ||||
- Filed herewith.
** Furnished herewith.
† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.